NCT06043830CompletedPhase 2
Managing Opioid Related Sleep Apnea With Acetazolamide
Source: ClinicalTrials.gov · Last updated 10 Mar 2026
Brief summary (registry, in English)
Patients with chronic pain who use opioids appear to be at increased risk for breathing issues during sleep, termed sleep disordered breathing (SDB). Treatment of SDB often consists of use of a device during sleep that provides continuous positive airway pressure (CPAP) via a mask interface. However, this device is not effective or tolerated in all individuals. The goal of this study is to examine whether a medication called acetazolamide can improve SDB, as an alternative to CPAP treatment. The investigators will measure the improvement in SDB, as well as any change in symptoms, during a 1 week treatment with acetazolamide compared with 1 week of placebo (sugar pill). This study will help to provide data for longer term studies of treatment for SDB in patients who use opioids.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- First submitted
- 12 Sept 2023
- Start date
- 18 Oct 2023
- Primary completion date
- 23 Dec 2025
- Lead sponsor
- University of California, San Diego
- NCT number
- NCT06043830
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 39
- From 18 Oct 2023 to the primary completion date, 23 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Urgent need to initiate effective SDB therapy
Other illness
- Chronic lung disease (other than well-controlled asthma)
- Active cardiac disease including heart failure, chest pain, or heart rhythm problems
- Major sleep disorders other than sleep apnea
- Chronic kidney disease
- Active cancer treatment or limited life expectancy
- Psychiatric disease other than controlled mood disorders
- Allergy to study drug or related compounds including sulfa drugs
Lab values
- Use of diuretics, potassium supplementation, or medications that may affect potassium
Other
- Use of opioids outside medical supervision (e.g. recreational use)
- Unable or unwilling to withhold any ongoing SDB treatment (e.g. CPAP) for the duration of the study
- Neurological or developmental problems affecting breathing
- Cirrhosis of the liver
- Know electrolyte disturbances
- Hospitalized in the last 90 days or anticipated hospitalization within 3 months
- Alcohol use \>2 standard drinks per day
- Presence of tracheostomy or artificial airway
- Prisoners
- Pregnancy or anticipating pregnancy in next 2 months, or nursing
- Unable or unwilling to provide informed consent
- Unable to follow study protocol
Who the study is looking for
- Age 18+
- Chronic pain
- Chronic opioid use (daily use for \>3 months duration) with \>/= 20 oral Morphine Equivalent Dose (MEqD) per day
- Apnea-hypopnea index \>/= 10 events/hr (hypopnea definition: ≥ 3% desaturation or arousal criteria per American Academy of Sleep Medicine 2012 scoring rules)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Diego Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.